Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Gardasil Trial Termination Is More Good News For Merck

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Data and safety monitoring board’s recommendation to switch placebo patients in FUTURE studies to the vaccine comes on the heels of an “approvable” letter for Novartis’ potential Januvia competitor Galvus.

You may also be interested in...



GlaxoSmithKline Submits Cervarix BLA

GSK has requested a priority review for the human papilloma virus vaccine, company tells “The Pink Sheet” DAILY.

GlaxoSmithKline Submits Cervarix BLA

GSK has requested a priority review for the human papilloma virus vaccine, company tells “The Pink Sheet” DAILY.

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

See All
UsernamePublicRestriction

Register

PS065686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By